Business
Trevi Therapeutics Announces Second Quarter 2021 Financial Results and Business Update
Phase 2b/3 PRISM (Chronic Pruritus in PN) Trial Approximately 80% Enrolled, Top-Line Data Readout Expected First Half of 2022 Phase 2 CANAL (Chronic Cough in
About this update from Trevi Therapeutics, Inc.
[{"type":"text","content":"Phase 2b/3 PRISM (Chronic Pruritus in PN) Trial Approximately 80% Enrolled, Top-Line Data Readout Expected First Half of 2022\n Phase 2 CANAL (Chronic Cough in IPF) Trial Recruiting, Top-Line Data Readout Expected First Half of 2022\n\n\nNEW HAVEN, Conn., Aug. 12, 2021 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of an investigational therapy Haduvio™ (nalbuphine ER) to treat serious neurologically mediated conditions, today announced financial results for the quarter ended June 30, 2021, as well as business updates.\n\n \n \n \n \n \n \n\n \nPruritus in PN (PRISM) Trial 80% enrolled and top-line data readout expected in 1H 2022\"We continue to advance both our pruritus in prurigo nodularis (PN) and chronic cough in idiopathic pulmonary fibrosis (IPF) trials,\" said Jennifer L. Good, President and CEO of Trevi Therapeutics. \"We are particularly pleased to see recruitment and enrollment activity resume in our CANAL trial with the lifting of COVID-19 restrictions in the UK. As a result of this activity, we have announced guidance for reporting top-line data on the CANAL trial in the first half of 2022.\" \nIn addition, Trevi recently announced two new additions to its management team. \"Trevi is pleased to have welcomed Lisa Delfini as our Chief Financial Officer and Danine Summers who joined us full time as our VP of Medical Affairs. We look forward to utilizing their deep experience as we grow the Company,\" added Ms. Good.\nKey Business Updates\nPhase 2b/3 PRISM trial of Haduvio for severe pruritus in patients with PN Approximately 285, or 80%, of planned subjects have enrolled Enrollment expected to be completed by the end of 2021 Top-line data readout expected in the first half of 2022 Phase 2 CANAL trial of Haduvio for chronic cough in patients with IPF Ongoing recruitment and screening taking place at multiple sites in the UK Top-line data readout expected in the first half of 2022 Expanded leadership team to support the growth of the CompanySecond Quarter 2021 Financial Highlights\nCash position: As of June 30, 2021, the Company had total cash and cash equivalents of $36.4 million, compared to $45.0 million as of December 31, 2020. \nResearch and development (R&D) expenses: R&D expenses for the second quarter of 2021 we...